What Abaloparatide is
Abaloparatide is a PTHrP analog used in approved bone-health contexts and sits beside teriparatide in osteoanabolic peptide medicine.
Abaloparatide is grouped under Approved / Clinical on PeptideFactCheck because it helps show how short peptide analogs can become highly targeted endocrine medicines.
The useful starting point is to separate the molecule itself from the internet story around it. It helps show how short peptide analogs can become highly targeted endocrine medicines.
Why people keep looking it up
It helps show how short peptide analogs can become highly targeted endocrine medicines.
Abaloparatide is a PTHrP analog used in approved bone-health contexts and sits beside teriparatide in osteoanabolic peptide medicine.
Abaloparatide tends to stay in the conversation because it touches a familiar public theme: pth receptor, bone formation, and osteoanabolic. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved osteoanabolic peptide analog with direct human evidence.
Human trials and labeling support specific approved uses.
Mechanism aligns with PTH receptor pharmacology and bone-remodeling biology.
Why this page carries the current tier: Approved osteoanabolic peptide analog with direct human evidence.
The current seed trail for Abaloparatide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Bone-active endocrine drugs need label-specific reading rather than generic anabolic language.
FDA-approved abaloparatide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Abaloparatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Abaloparatide is CID 76943386. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 76943386
- Formula
- C174H300N56O49
- Molecular weight
- 3961
- InChIKey
- BVISQZFBLRSESR-XSCWXTNMSA-N
Matched synonyms include Abaloparatide, Tymlos, BA058, 247062-33-5, BIM-44058, AVK0I6HY2U, abaloparatida, abaloparatidum.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Abaloparatide returns 23 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Abaloparatide returns 393 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Tymlos
- Generic names
- ABALOPARATIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA208743
Indications and usage. 1 INDICATIONS AND USAGE TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intoler...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Osteosarcoma: Avoid use in patients with increased risk of osteosarcoma including patients with open epiphyses, metabolic bone diseases including Paget's disease, bone metastases or history of skeletal malignancies, prior external beam or implant radiation therapy involving the skeleton, and hereditary disorders predisposing to osteosarcoma. ( 5.1 ) Orthostatic Hypotension: Instruct patien...
Contraindications. 4 CONTRAINDICATIONS TYMLOS is contraindicated in patients with a history of systemic hypersensitivity to abaloparatide or to any component of the product formulation. Reactions have included anaphylaxis, dyspnea, and urticaria [see Adverse Reactions ( 6.2 )] . Known hypersensitivity to TYMLOS. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.